Staphylococcus haemolyticus in Urine: Pathogenesis and Treatment

Staphylococcus haemolyticus is a skin-dwelling bacterium that rarely causes urinary tract infections on its own but can become a serious problem in hospitalized patients, particularly those with urinary catheters. When it does infect the urinary tract, its ability to form tough biofilms on catheter surfaces and its exceptional resistance to antibiotics make it harder to treat than the staphylococci more commonly blamed for urinary infections. The organism sits in a strange niche: it is part of normal skin flora yet ranks among the most antibiotic-resistant of the coagulase-negative staphylococci found in hospitals.

Why S. Haemolyticus Shows Up in Urine Cultures

Urinary tract infections caused by staphylococci are most often attributed to Staphylococcus saprophyticus in otherwise healthy young women and to Staphylococcus epidermidis in hospital settings. S. haemolyticus is a less common culprit, and when it appears in a urine culture, the first clinical question is whether it represents true infection or contamination from skin flora during sample collection. Because S. haemolyticus is one of the most abundant staphylococcal species on human skin, it can easily enter a urine sample if collection technique is imperfect.¹

True urinary infections from S. haemolyticus tend to occur in specific circumstances. The organism is overwhelmingly associated with healthcare settings and is widespread among hospital staff and on surfaces, making it a classic opportunist. A documented case report of a persistent S. haemolyticus urinary tract infection in a 38-year-old man illustrated that the organism can cause genuine, symptomatic infection of the urinary tract, though such cases remain unusual outside hospital-acquired scenarios.² The patients at greatest risk are those with indwelling urinary catheters, recent urological procedures, or compromised immune systems. The catheter surface gives S. haemolyticus something it needs to thrive: a physical scaffold on which to build a biofilm.

How It Causes Infection Without the Usual Tricks

One of the more surprising findings about S. haemolyticus in the urinary tract is that it lacks the adhesion advantage that makes Staphylococcus saprophyticus such a successful urinary pathogen. In laboratory experiments, S. saprophyticus readily adhered to human ureteral epithelium using pili-like surface structures, while S. haemolyticus, along with S. epidermidis, did not adhere to the epithelial surface at all.³ This means S. haemolyticus is not naturally suited to colonizing urinary tract tissue the way S. saprophyticus is. Instead, it depends almost entirely on foreign surfaces like catheter tubing to gain a foothold.

Once on that surface, the organism’s primary weapon is biofilm formation. Biofilm is a sticky matrix of proteins, DNA, and sometimes polysaccharides that bacteria secrete around themselves, creating a community that is remarkably difficult to penetrate with antibiotics or immune cells. In S. haemolyticus, biofilm structure is different from that of its close relative S. epidermidis: proteins and extracellular DNA are the major structural components, rather than the polysaccharide intercellular adhesin (PIA) that dominates S. epidermidis biofilms. In a study of clinical S. haemolyticus isolates, enzymes that degrade DNA detached 100% of biofilms, and protein-degrading enzymes detached 98%, whereas a sugar-targeting agent only disrupted 38%.⁴ This distinction matters for treatment, because strategies designed to break up polysaccharide-based biofilms may not work as well against S. haemolyticus.

Beyond biofilm, S. haemolyticus produces additional virulence factors. Pathogenic isolates secrete hemolysins, enterotoxins, and fibronectin-binding proteins that help with tissue invasion and immune evasion.¹ Among S. haemolyticus isolates from urinary tract infections in one study, about a third carried the biofilm-associated icaD gene, roughly one in ten carried the gene encoding Panton-Valentine leucocidin (a toxin that destroys white blood cells), and about 8% carried the gene for fibronectin-binding protein A.⁵ The Panton-Valentine leucocidin finding, while present in only a small fraction of isolates, is concerning because this toxin is more commonly associated with aggressive Staphylococcus aureus infections and is unusual in coagulase-negative species.

The Antibiotic Resistance Problem

S. haemolyticus is widely considered the most antibiotic-resistant of all the coagulase-negative staphylococci, and this resistance is the single biggest reason clinicians worry about it in any infection, urinary or otherwise. In a study of clinical isolates from a major hospital, 87% carried the mecA gene, meaning they were methicillin-resistant. The majority of those harbored a specific mobile genetic element (SCCmec type V) that carries and spreads resistance genes.⁶ In a separate survey at a hospital in Thailand, S. haemolyticus accounted for nearly half of all oxacillin-resistant coagulase-negative staphylococci, far outpacing S. epidermidis and other species.⁷

Methicillin resistance means that the entire family of beta-lactam antibiotics, the most commonly prescribed class of drugs for staphylococcal infections, is ineffective. When methicillin-resistant S. haemolyticus causes a urinary tract infection, clinicians typically turn to vancomycin as a backup. But even that safety net has begun to fray. Researchers have documented emerging heteroresistance to vancomycin in some S. haemolyticus blood isolates, meaning a small subpopulation of cells within a single infection can survive vancomycin concentrations that kill the majority.⁸ Earlier laboratory work had already shown that S. haemolyticus strains could be coaxed into progressively higher levels of glycopeptide resistance, with vancomycin minimum inhibitory concentrations reaching levels well above the clinical breakpoint.⁹

Part of what makes S. haemolyticus so adept at accumulating resistance is its remarkably plastic genome. Whole-genome sequencing identified as many as 82 insertion sequences scattered across the S. haemolyticus chromosome, far more than in most related species. These mobile DNA elements shuffle genes around, allowing the bacterium to acquire and rearrange resistance genes at an unusually high rate.¹⁰ Some of these insertion sequences have been linked to specific resistance genes, including rare ones like cfrA, which confers resistance to multiple antibiotic classes simultaneously.¹¹ In practical terms, this genomic flexibility means that S. haemolyticus can evolve resistance during the course of a single patient’s treatment, a scenario that turns what might seem like a straightforward urinary infection into a recurring problem.

How Labs Identify It

Accurate identification of S. haemolyticus matters because its resistance profile is dramatically different from other coagulase-negative staphylococci that might also turn up in a urine culture. Traditional biochemical tests can struggle to distinguish among the many staphylococcal species. Modern clinical laboratories increasingly rely on a technology called MALDI-TOF mass spectrometry, which identifies bacteria by their protein fingerprint in minutes rather than days. This method performs well for S. haemolyticus, though results can depend on the sample preparation method used. One study comparing approaches found that a protein extraction method significantly improved identification scores for staphylococci, including S. haemolyticus, compared to simply smearing intact colonies directly onto the analysis plate.¹²

Molecular methods using PCR can also confirm species identity. Researchers have developed multiplex PCR assays targeting species-specific genes alongside the mecA resistance gene, allowing simultaneous identification of S. haemolyticus and its methicillin resistance status in a single test.¹³ These combined approaches mean that once S. haemolyticus is identified in a urine sample, the lab can quickly flag whether it carries methicillin resistance, giving clinicians early guidance on which antibiotics to avoid.

Treatment of Urinary Tract Infections

Treatment depends on whether the infection is catheter-associated, how resistant the particular isolate turns out to be, and whether biofilm is involved. For uncomplicated cases where the organism is still sensitive to common antibiotics, older drugs can work. In the documented male UTI case mentioned earlier, the persistent infection was ultimately resolved with trimethoprim-sulfamethoxazole, a widely available oral antibiotic.² But most hospital-acquired S. haemolyticus isolates will not be this cooperative. When susceptibility testing shows methicillin resistance, vancomycin is the standard choice for serious infections. Linezolid and daptomycin are additional options reserved for complicated cases or when vancomycin sensitivity is questionable.

Catheter removal or replacement is a critical step whenever possible. Because S. haemolyticus relies so heavily on catheter surfaces for biofilm formation, leaving the contaminated device in place allows the biofilm community to persist and continuously seed the urine with bacteria, even under antibiotic pressure. No antibiotic regimen reliably eradicates a mature biofilm on an indwelling device. Removing the source is often more effective than adding more drugs.

For situations where the catheter cannot be removed, researchers have investigated combination antibiotic strategies that might penetrate biofilms more effectively. In laboratory testing, rifampicin combined with tigecycline showed greater activity against S. haemolyticus biofilms than rifampicin paired with daptomycin, with the tigecycline combination being two to five times more effective against most tested strains.¹⁴ These are laboratory findings rather than results from clinical trials in patients with urinary infections, so they should be viewed as suggestive rather than definitive.

Experimental Anti-Biofilm Approaches

The difficulty of treating biofilm-associated infections with conventional antibiotics has pushed researchers toward unconventional strategies. One promising line of work involves bacteriocins, which are antimicrobial proteins naturally produced by bacteria to kill competing species. A three-component bacteriocin combination was tested against S. haemolyticus in the laboratory and completely eradicated biofilm-associated cells in vitro. The individual bacteriocins and two-component combinations were not particularly effective, but the three together produced a dramatic drop in living cells within biofilms. Perhaps more importantly, the combination prevented the development of resistant mutants, a persistent problem with conventional antibiotics.¹⁵

Another experimental approach pairs conventional antibiotics with antimicrobial peptides. Combining the antimicrobial peptide nisin with oxacillin reduced the concentration of oxacillin needed to eradicate staphylococcal biofilms by eight- to 32-fold and inhibited the expression of biofilm-related genes.¹⁶ While that particular study focused on S. epidermidis and S. aureus biofilms, the approach is being explored across staphylococcal species. None of these experimental strategies are available in clinical practice yet, but they reflect how seriously the biofilm problem is taken in the research community.

Distinguishing True Infection from Contamination

One of the most practical questions for anyone who has seen S. haemolyticus on a urine culture report is whether it actually means anything. Because this organism lives on everyone’s skin, a single positive culture with low colony counts may simply reflect skin contamination during sample collection. Clinicians typically look for several features before deciding the result represents real infection: a colony count above a certain threshold (often 100,000 colonies per milliliter, though lower thresholds apply for catheterized patients), the presence of white blood cells in the urine, and symptoms consistent with a urinary infection such as fever, urgency, or flank pain.

In catheterized patients, the interpretation gets murkier. Asymptomatic bacteriuria, where bacteria grow in the urine without causing symptoms, is extremely common in people with catheters and generally does not require treatment. Treating every positive culture with antibiotics would drive even more resistance. Current clinical practice in most guidelines recommends treating catheter-associated urinary infections only when symptoms are present, and removing or changing the catheter as part of that treatment.

Why S. Haemolyticus Is Becoming More Common in Clinical Settings

S. haemolyticus has always been on human skin, so its presence is not new. What has changed is the hospital environment. The widespread use of broad-spectrum antibiotics, the proliferation of invasive devices like catheters and central lines, and the increasing survival of immunocompromised patients have all created conditions that favor organisms like S. haemolyticus. Its genomic plasticity, driven by those dozens of insertion sequences, allows it to adapt to antibiotic pressure faster than most other coagulase-negative staphylococci.¹⁰ S. haemolyticus strains causing hospital infections tend to be substantially more resistant than isolates found on healthy skin in the community, suggesting that the hospital environment selects for the most resistant lineages.¹

This organism also has the unsettling habit of persisting on hospital surfaces and the hands of healthcare workers, creating a reservoir for ongoing transmission. Some genomic studies have documented spontaneous large-scale deletions in the S. haemolyticus genome during hospital persistence, suggesting the bacterium actively reshuffles its DNA as a survival strategy in the face of environmental pressure.¹⁷ The practical consequence is that infection-control measures like hand hygiene and device stewardship are just as important as antibiotic choices in managing S. haemolyticus. You can pick the right drug for a given isolate, but if the hospital environment keeps seeding new infections, the problem recurs.

S. Haemolyticus Compared to Other Staphylococci in Urinary Infections

The reason S. haemolyticus gets less attention than other staphylococci in the urinary tract is largely a matter of frequency. S. saprophyticus is the dominant staphylococcal cause of community-acquired urinary infections, particularly in young women. It has a natural ability to stick to the lining of the urinary tract using surface structures that S. haemolyticus lacks.³ S. epidermidis, like S. haemolyticus, primarily causes catheter-associated infections, but its biofilm relies more on polysaccharide than protein. S. aureus can invade the urinary tract through the bloodstream during sepsis and is associated with more severe tissue damage.

Where S. haemolyticus stands out from its relatives is in resistance. It consistently shows higher rates of methicillin resistance than S. epidermidis in the same hospital settings and more readily develops reduced susceptibility to vancomycin.⁶ For urinary infections specifically, this means that an S. haemolyticus UTI is less likely to respond to empiric antibiotic therapy and more likely to require susceptibility-guided treatment. It also means that isolation of S. haemolyticus in a hospital urine culture should prompt a closer look at the patient’s catheter status and a lower threshold for device removal.

There is also a concern about gene transfer. Because S. haemolyticus is so adept at acquiring and harboring resistance genes, some researchers worry it could serve as a reservoir, passing resistance genes to other staphylococci sharing the same hospital niche. This has not been definitively demonstrated in the urinary tract, but the principle of horizontal gene transfer among coagulase-negative staphylococci is well established, and S. haemolyticus’s genome is particularly well equipped for it.¹¹

1
PubMed Central. Clinical Infections, Antibiotic Resistance, and Pathogenesis of Staphylococcus haemolyticus
2
PubMed Central. Staphylococcus haemolyticus urinary tract infection in a male patient
3
PubMed. In vitro adherence of Staphylococcus saprophyticus, Staphylococcus epidermidis, Staphylococcus haemolyticus, and Staphylococcus aureus to human ureter
4
PubMed Central. Biofilm formation by Staphylococcus haemolyticus
5
Acta Microbiologica Bulgarica. Prevalence of Multidrug-Resistant Staphylococcus Haemolyticus isolates and Their Virulence Factors in Urinary Tract Infections in Saudi Arabia
6
PubMed Central. Staphylococcus haemolyticus as an important hospital pathogen and carrier of methicillin resistance genes
7
New Microbes and New Infections. Prevalence of methicillin resistance and macrolide–lincosamide–streptogramin B resistance in Staphylococcus haemolyticus among clinical strains at a tertiary-care hospital in Thailand
8
PubMed Central. Detection of Heteroresistant Vancomycin-Intermediate Staphylococcus haemolyticus Among Blood Isolates
9
PubMed Central. Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics
10
PubMed Central. Whole-genome sequencing of staphylococcus haemolyticus uncovers the extreme plasticity of its genome and the evolution of human-colonizing staphylococcal species
11
PubMed. In-silico genomic characterization of Staphylococcus haemolyticus on a global scale: lineages, resistome, and virulome
12
Clinical Microbiology and Infection. Rapid method for direct identification of bacteria in urine and blood culture samples by matrix-assisted laser desorption ionization time-of-flight mass spectrometry: intact cell vs. extraction method
13
FEMS Immunology & Medical Microbiology. Multiplex PCR assay to identify methicillin-resistant Staphylococcus haemolyticus
14
PubMed Central. In Vitro Activity of Rifampicin Combined with Daptomycin or Tigecycline on Staphylococcus haemolyticus Biofilms
15
Scientific Reports. A bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms
16
PubMed Central. Combination antimicrobial therapy: in vitro synergistic effect of anti-staphylococcal drug oxacillin with antimicrobial peptide nisin against Staphylococcus epidermidis clinical isolates and Staphylococcus aureus biofilms
17
bioRxiv. Spontaneous genomic variation as a survival strategy of nosocomial S. haemolyticus